This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
It’s been a while since I wrote a “Mean Adam” newsletter.
The biotech company Clene is developing a treatment for ALS called CNM-Au8 that it describes as a “highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals.”
Allow me to translate: The Clene “drug” is gold microdust suspended in water.